Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
Recruiting now · Phase 4
Conditions studied: Metastatic Breast Cancer, Metastatic Prostate Cancer
In brief
The REaCT-CHRONO-MetBP Pilot study will compare morning and evening administration of endocrine-based therapy in metastatic breast and prostate cancers. Participants with metastatic breast or prostate cancer will be randomly placed in one of two groups: a morning group and an evening group. The group assignment will determine whether they take their endocrine therapy in the morning or the evening. The primary outcome of this pilot study is to evaluate the feasibility of study procedures in order to conduct a larger definitive trial in the future. The secondary outcomes include comparing quality of life, tolerability, and efficacy outcomes between the morning and evening groups for each of the two cancer cohorts (metastatic breast and prostate cancer).
Key facts
- Study ID
- NCT07252726
- Run by
- Ottawa Hospital Research Institute
- People needed
- 50
- Starts
- 2026-02-02
- Expected to finish
- 2033-03-01
- Last updated by the study team
- 2026-07-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Waterloo Regional Health Network — Kitchener, Ontario, Canada (enrolling)
- The Ottawa Hospital Cancer Centre — Ottawa, Ontario, Canada (enrolling)
- Saskatoon Cancer Centre — Saskatoon, Saskatchewan, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.